Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2023-04-03
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-30 (study day 52); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-04 (study day 87); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-22 (study day 167); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-27 (study day 233); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-05-08 (study day 396); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.